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Available online 1 May 2020The current pandemic is not only overwhelming the health systems
of the affected countries but also is killing thousands of other ways
healthy adults. Convalescent plasma has been proposed [1] and
approved to treat COVID-19 based on the experience acquired treating
other viral diseases such as influenza, Ebola, and SARS [2]. It is consid-
ered a safe treatment (at least its side effects and contraindications are
well known) and it has proven to be efficacious in several viral infec-
tions for more than a century. Currently, several countries and health
institutions are trying to gather convalescent sera for either empirical
treatment or clinical trials. Based on the WHO interim guidance devel-
oped for the 2014 Ebola outbreak [3], convalescent plasma has advan-
tages over other proposed treatment: it requires low technology (and
therefore it can be produced where required independent of pharma-
ceutical companies), it is low cost and its production is easily scalable as
long as there are sufficient donors.
In other words, relative donor scarcity can threaten any plan to mas-
sively produce treatments based on plasma. Due to the exponential
nature of the pandemic, the number of current patients is greater than
the number of recovered patients at any given time until the peak is
reached. The number of identified recovered patients equals approxi-
mately the number of identified active patients three weeks earlier
minus the deaths. In a supposed population with a steady growth of
identified contagions of 20% something similar to what is currently going
on in several cities around the world the number of active patients is
between 17 and 87 times greater than the number of identified recov-
ered patients (potential donors). This means, in the best case scenario,
there would be convalescent plasma available for 15% of the identified
current patients. The actual number of donors will probably be much
lower as not every convalescent patient willing to donate would be suit-
able (a great proportion are elder and have comorbidities) and not every
suitable potential donor will be willing to donate.
Fortunately, infection by SARS-CoV2 is not as lethal as that caused
by Ebola virus and many patients do not require treatment to* Corresponding author.
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patients may be much greater than the number based on the recov-
ery of previously identified patients because of the existence of
asymptomatic and mild infections. This might be especially true in
countries where most of the incident infections had been acquired
from not previously identified cases. This is currently the case in sev-
eral western countries. The estimates from the Imperial College Lon-
don COVID-19 Response Team also support the hypothesis that most
of the cases go unrecognized. According to their calculations, among
11 European countries (comprising 375 million citizens) as of March
30th there were about 18 million cases [4]. Populations that have
been fully or randomly tested confirm the existence of asymptomatic
infections [57]. Accordingly, we propose two sources of donors, not
frequently identified, should be explored: paucisymtomatic patients:
and fully asymptomatic patients.
Serosurveys might identify as many donors as required for the
growing number of patients who could benefit from convalescent
plasma. Serosurveys have been used to evaluate the immunity of
some populations to infections such as Ebola and SARS after con-
trolling the outbreaks. They are very useful to evaluate the suscep-
tibility of a population and therefore to calculate the peak of a
current or subsequent outbreak using the SIR model (susceptible,
infectious and recovered compartments) estimating the size of the
recovered compartment. This in turn is used to decide health poli-
cies. To our knowledge, serosurveys have not been used to drive
plasma donations. In these diseases, known to have greater mor-
tality, a significant proportion of asymptomatics has been found
seropositive among exposed populations [8,9].
To boost the ability of serosurveys to find potential donors, the
approach could be modified to enrich the sample (albeit not obtain-
ing representative data). Targeting populations at high risk of expo-
sure such as contacts or health workers and self-identification of
potentially convalescent patients using questionnaires could easily
lead to as many plasma donors as required before the number of con-
tagions peaks.
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